Analysts expect Chemours to report Q3 2026 consensus revenue of $1.53 billion and adjusted EPS of $0.27, representing a significant year-over-year bottom-line improvement. The stock's current price of approximately $13.35 remains well below the average analyst target of $16.50 as the company works to regain investor confidence following recent guidance cuts.
The primary focus for this report is the performance of the Thermal & Specialized Solutions (TSS) segment and the progress of Opteon refrigerant channel destocking.
Investors are cautious after management lowered full-year 2026 expectations in August, citing an oversupplied aftermarket channel for its flagship Opteon blends. Markets are seeking confirmation that this inventory glut is clearing, alongside updates on litigation settlements and the 'Pathway to Thrive' cost-saving initiative.